ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development
August 31 2020 - 9:00AM
Business Wire
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the
appointment of Dr. Gudarz Davar as Executive Vice President and
Head of Research and Development. Dr. Davar will be responsible for
leading research and development activities at ACADIA and will
serve as a member of the company’s Executive Management Committee.
In this role, he will report to Serge Stankovic, M.D., M.S.P.H.,
President of ACADIA. Dr. Stankovic will continue to oversee
research and development, regulatory, medical affairs, external
innovation and pharmacovigilance functions for the company.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200831005180/en/
Gudarz Davar, M.D., Executive Vice
President and Head of Research and Development (Photo: Business
Wire)
“We are thrilled to welcome Gudarz to ACADIA’s executive team as
a senior neurologist and neuroscientist with strong scientific,
academic and corporate leadership experience,” said Steve Davis,
ACADIA’s Chief Executive Officer. “As we prepare for the potential
approval and launch in the U.S. of our second indication for
pimavanserin, the treatment of hallucinations and delusions
associated with dementia-related psychosis, we continue to focus on
developing innovative new treatments to address unmet needs. Gudarz
will be a valuable addition to our executive team as we execute and
grow our pipeline to drive long-term growth.”
“I share ACADIA’s passion for improving the lives of patients
with central nervous system disorders and am particularly excited
to use my experience to strengthen the breadth and depth of
ACADIA’s pipeline,” said Dr. Davar.
Dr. Davar joins ACADIA from Eli Lilly where he was Vice
President, Head of Global Neurology Clinical Development, the
senior leadership role responsible for the global development of
all neuroscience and core Lilly biomedicines assets through
clinical testing and life of the product. Under his leadership were
the recent global approvals of Emgality® for migraine prevention
and U.S. approval for the treatment of cluster headache, as well as
the U.S. approval of REYVOW® as a first-in-class, novel, acute
treatment for migraine.
Prior to Eli Lilly, he served in senior leadership roles in
neurology and clinical development at Allergan, Biogen Idec and
Amgen. At Allergan, he led a global research and development and
commercialization partnership focused on cognitive impairment and
neurobehavioral symptoms in Alzheimer's disease.
Dr. Davar received his medical degree from Dalhousie University
in Halifax, Nova Scotia. He completed residency at University of
Michigan Hospitals, Ann Arbor, Michigan and is board certified in
Neurology.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in central nervous system disorders. ACADIA has
developed and commercialized the first and only medicine approved
for the treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis. ACADIA’s development efforts are
focused on pimavanserin for additional neuropsychiatric conditions,
trofinetide for Rett syndrome, ACP-044 for pain management and an
early-stage muscarinic receptor program. This press release and
further information about ACADIA can be found at:
www.acadia-pharm.com.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements regarding the
timing of future events. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in
drug development, approval and commercialization. For a discussion
of these and other factors, please refer to ACADIA’s annual report
on Form 10-K for the year ended December 31, 2019 as well as
ACADIA’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise
or update this press release to reflect events or circumstances
after the date hereof, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200831005180/en/
Media Contact: ACADIA Pharmaceuticals Inc. Eric Endicott (858)
914-7161 media@acadia-pharm.com
Investor Contact: ACADIA Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771 ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2023 to Sep 2024